Poster to be presented Sunday, December 10, 2023
CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- K36
Therapeutics, Inc. ("K36"), a clinical-stage biotech company
focused on developing its first-in-class MMSET inhibitor KTX-1001
for t(4;14) multiple myeloma, today announced that its abstract
evaluating KTX-1001 in relapsed and refractory multiple myeloma has
been accepted for presentation at the 65th American
Society of Hematology (ASH) Annual Meeting and Exposition, which
will be held December 9-12, 2023, in
San Diego, California, and online.
Dr. Jesús G. Berdeja, the Director of Multiple Myeloma Research at
Tennessee Oncology, will deliver the presentation as part of the
Trials in Progress session.
"I am delighted to be presenting the trial progress of KTX-1001
in high-risk subsets like translocation t(4;14)," stated Dr.
Berdeja. "There still remains an unmet need for new personalized
oral therapies to treat multiple myeloma and novel precision
therapeutics like KTX-1001 to address the challenges seen in
high-risk patients with translocation t(4;14)."
"We are seeing significant interest and momentum in our Phase 1
trial, and I would like to thank the patients, investigators and
their staff for their commitment to generate important data from
our trial," said Terry Connolly,
Ph.D., Chief Executive Officer of K36. "KTX-1001 has demonstrated
encouraging preclinical activity and a favorable tolerability
profile establishing the potential to create a breakthrough therapy
for multiple myeloma patients who have exhausted available standard
of care treatments."
Presentation Details:
Title: Trial in Progress: A Phase 1 Study of
KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in
Patients with Relapsed and Refractory Multiple Myeloma
Poster Number: 3391
Session Name: 653. Multiple Myeloma: Prospective Therapeutic
Trials: Poster II
Date: Sunday, December 10,
2023
Time: 6:00 PM - 8:00 PM PT
Location: San Diego Convention Center, Halls G-H
Full abstracts can be found at the ASH Annual Meeting website
at www.Hematology.org.
About KTX-1001
KTX-1001 is a novel, first-in-class,
potent, and selective methyltransferase inhibitor of the catalytic
activity of lysine H3K36. It is an orally administered small
molecule being developed initially for the treatment of relapsed
and refractory multiple myeloma, with a focus on patients with the
t(4;14) translocation. This inhibitor offers a promising avenue for
addressing this challenging high risk patient population.
About the KTX-1001 Phase 1 Clinical Trial
The Phase 1
clinical trial is a single-arm, open-label study in subjects with
relapsed and refractory multiple myeloma. It is a multi-part
clinical trial with dose escalation followed by an expansion cohort
in patients with the genetic translocation t(4;14) to evaluate the
safety, tolerability, and preliminary efficacy of different doses
of KTX-1001. For more information and participating centers visit
NCT05651932.
About K36 Therapeutics, Inc.
Founded in February
2021, K36 is a privately held biotech company backed by Atlas
Venture, F-Prime Capital, Eight Roads Capital, Nextech and Bristol
Myers Squibb (NYSE:BMS). Our mission
is to translate epigenetic modulation of oncogenic pathways into
first-in-class small molecule therapeutics for the benefit of
cancer patients worldwide. For more information, please
visit www.k36tx.com and follow us on LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/k36-therapeutics-announces-presentation-on-ktx-1001-for-relapsed-and-refractory-multiple-myeloma-at-the-65th-american-society-of-hematology-ash-annual-meeting-302003926.html
SOURCE K36 Therapeutics